Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Eur J Cancer. 2021 Feb 16;146:125–134. doi: 10.1016/j.ejca.2020.12.031

Figure 3.

Figure 3.

LAMC2 expression predicts therapeutic response to gemcitabine-based therapy. (A) Waterfall plots for predicting best tumor response in PDAC patients treated with gemcitabine and nab-paclitaxel as a primary treatment. (B) Comparison of LAMC2 expression levels in responders and non-responders in the primary chemotherapy cohort. (C) The proportion of responders and non-responders in the LAMC2-high and low patients. (D) ROC curves for the predicting therapeutic response to gemcitabine. Kaplan-Meier curves for (E) OS and (F) PFS in PDAC patients with high (pink) or low (blue) LAMC2 expression in the primary chemotherapy cohort. *, P<0.05; **P<0.001.